August 24, 2026  Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due

Philips prices EU green bond for EUR 650M

Philips prices EUR 650m 2034 Green Bond under new EU Standard

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 August 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Royal Philips announced pricing of EUR 650 million fixed-rate notes due 2034, the healthcare sector&#039;s first under the European Green Bond Standard. The note issue temporarily increases gross debt but is not expected to lift net debt; proceeds will fund taxonomy-aligned activities aligned with Philips&#039; 2030 Ambition. Settlement is August 28, 2026, with a Luxembourg listing planned.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Philips priced EUR 650m 2034 notes; first EU Green Bond under new standard.</li><li>Gross debt temporarily increases; net debt not expected to rise.</li><li>7.8-year tranche oversubscribed 2.7x; settlement August 28, 2026.</li><li>Proceeds fund taxonomy-aligned activities per 2030 Impact Ambition.</li><li>Notes listed on Luxembourg Stock Exchange; Philips maintains investment-grade ratings.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Royal Philips (PHG): Pricing of EUR 650m 2034 Green Bond; supports 2030 Ambition; debt management.</li><li>Royal Philips (PHIA): AEX listing; notes issuance will be listed; cross-listing implications.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 Category: Corporate Developments. This financing event demonstrates Philips&#039; ability to raise green funds under a new EU standard, signaling ESG alignment and financing flexibility that could influence cost of capital and investor perception.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Oversubscription of 2.7x signals strong investor appetite for Philips debt.</li><li>EU Green Bond Standard endorsement may attract ESG funds.</li><li>Luxembourg listing could affect near-term note liquidity.</li><li>Near-term net debt impact is negative but offset by green-proceeds.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>EUR 650 million fixed-rate notes due 2034.</li><li>Issue price 99.655%; coupon 4.0%; yield 4.055%.</li><li>Tranche duration 7.8 years; oversubscribed 2.7x.</li><li>Settlement date: August 28, 2026; Luxembourg listing planned.</li><li>Green Bond under European Green Bond Standard; aligns with 2030 Impact Ambition.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish near-term for PHG on ESG optics and debt flexibility within 12 months.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>August 24, 2026 Amsterdam, the Netherlands – <a href="https://www.globenewswire.com/Tracker?data=73GeMLP_kw5dRzCw-8lBPmx5V1OhxHFvNAI848HLVrjx58u5aJLymPdL49xtQX1EITNKfXS5OejqE3mY-wUzEMhuguYNmU3nP0yGEmudhag=" rel="nofollow" target="_blank">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/PHG">PHG</a>, AEX: PHIA)), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the "Notes") under its European Medium Term Note (EMTN) program. The Notes are the healthcare industry&#39;s first EU Green Bond under the new European Green Bond Standard. This issuance is not expected to result into an increase of Net Debt. Gross Debt will be temporarily increased until repayment of the 2027 bond maturity in May 2027. The issue price for the Notes due 2034 is 99.655% with a Coupon of 4.0%, resulting in a yield of 4.055%. The 7.8 year tranche was oversubscribed by 2.7 times. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in <a href="https://www.globenewswire.com/Tracker?data=JCmcduYQEe7IusRhfi-qquJ4eMOR0QEMWuJmf-VFthMiwjfWL9eXU0uPE3tKD7fjOWZHhwO4QEbn0pAQeAsXikswSNihmPOt3iuIKZcqNRZF4VV6qoGrtZ1xK9rnPFFmPL15pH2jsIC2ZD96MFKnT-rH6kNx884GKaPj-bW8oRZ8TFaf73e4m7PDR1k8xAEWti9qDWYUvIk06-WnDL1bFzmyvsDcgCEmF05b2Y2h_mzA_POO_HbIAT7_65BMZn6e" rel="nofollow" target="_blank">Philips European Green Bond Factsheet</a>, supporting Philips in delivering on its <a href="https://www.globenewswire.com/Tracker?data=R6d7THCXguer4D0Sxhc1h-Ly48MOYVM9KR78Can2NaOhF36K1CNvG_dLpC3P4dHZgDn1gR2UlypLCK0F2R6GhuJc0le2evN2_AMB-_LbOtlVEk966xTLFYHNrBNpWNFecdnvuVKduSZx3V9qVoSisMXC_v7hI7ry2GNs6jzaeU4=" rel="nofollow" target="_blank">2030 Impact Ambition</a>. Settlement and issue of the Notes is scheduled for August 28, 2026. Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and to be traded on the regulated market of the Luxembourg Stock Exchange.   Philips is committed to maintaining a strong investment grade credit rating. Currently, the company has a BBB+ rating by Standard &amp; Poor&#39;s (stable outlook), a Baa1 rating by Moody&#39;s (stable outlook) and a BBB+ rating by Fitch (stable outlook).  THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ‘SECURITIES ACT‘), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO REGISTER ANY SECURITIES REFERRED TO HEREIN IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES. PROHIBITION OF SALES TO EEA RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. PROHIBITION OF SALES TO UK RETAIL INVESTORS – The Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise  made available to any retail investor in the United Kingdom (the "UK"). For these purposes, a retail investor means a person who is not a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended, the "EUWA"). Consequently no disclosure document required by the FCA Product Disclosure Sourcebook ("DISC") for offering, selling or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024. In the UK, this press release is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this press release or any of its contents. Relevant stabilisation regulations including FCA/ICMA apply. MiFID II and UK MiFIR professionals/ECPs-only Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). For further information, please contact: Michael Fuchs Philips Global External Relations Tel.: +31 6 1486 9261 E-mail: <a href="https://www.globenewswire.com/Tracker?data=JWtgFtNThoVgrGx5Kfqj2b6yhOJjK_zXCgCMZIgWVbEJkYftyhr8LFZQPWUfGMerMMUP9AWP6f7c5VpMP7UySG9w55r4Mg2pATy54OgQkDiADNlBqwq5RZ7PFQ2C0hrt" rel="nofollow" target="_blank">michael.fuchs@philips.com</a> Dorin Danu Philips Investor Relations Tel.: +31 20 59 77055 E-mail: <a href="https://www.globenewswire.com/Tracker?data=yyJ8tdTok8lkAK2muyZdgB-20qgU2R1DjwhX-KwsP8jERluL1E76MNJvl7j8l1OCsiivcpN5YskPiVXFALQZZ4e4JMz5_cymxRwsrSoFIZo=" rel="nofollow" target="_blank">dorin.danu@philips.com</a> About Royal Philips Royal Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/PHG">PHG</a>, AEX: PHIA)) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at <a href="https://www.globenewswire.com/Tracker?data=kM1AI1W1DEBieVMkpz9Zf47DrJh9gvzeKtaEAB9-HklbYnVcb0v0yq_9a4jwEFttxdtpU8yvxgsLbyaVpVjFPmfVNAjUAg9k8XnLNDjfDyVfJf00XM8EaZ5t5Y3YoDhF" rel="nofollow" target="_blank">www.philips.com/newscenter</a>. Forward-looking statements This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTI1OTE0NiM0MDI0OTIxMTgjMjAwMjgwMg=="></img> <img alt="" src="https://ml-eu.globenewswire.com/media/ZTYzZDk3NGYtNDQ0Yy00MmJlLTgxMzYtNWM2MDI4MjNkNDllLTEwMTQzNzUtMjAyNi0wOC0yNC1lbg==/tiny/Philips-International-B-V-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e5826782-01bc-45e7-b448-9ca1eae0125e"><img src="https://ml-eu.globenewswire.com/media/e5826782-01bc-45e7-b448-9ca1eae0125e/small/philips-logo-logotype-emblem-700x128-png.png" border="0" width="150" height="27" alt="Primary Logo"></img></a>

Royal Philips announced pricing of EUR 650 million fixed-rate notes due 2034, the healthcare sector's first under the European Green Bond Standard. The note issue temporarily increases gross debt but is not expected to lift net debt; proceeds will fund taxonomy-aligned activities aligned with Philips' 2030 Ambition. Settlement is August 28, 2026, with a Luxembourg listing planned.

News insight

Philips prices EU green bond for EUR 650M

AI summary

Sentiment rationale

Key facts

Corporate Developments